Cyclo(RGDyK) trifluoroacetate
CAS: 250612-42-1
Ref. 3D-AKA61242
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
Cyclo(RGDyK) trifluoroacetate is a cilengitide that has been shown to inhibit tumor growth in xenografts. It binds to the cancer cell surface and inhibits the formation of heterodimers between integrin αvβ3 and its ligand, vitronectin. The inhibition of these heterodimer formation leads to an inhibitory effect on tumor angiogenesis. Cyclo(RGDyK) trifluoroacetate has been shown to have a high uptake in human serum, tissues, and tumors. This drug also has pharmacokinetic properties and molecular modeling studies have shown that it can be conjugated with positron-emitting isotopes for imaging. Cyclo(RGDyK) trifluoroacetate is taken up by MCP-7 cells at a higher rate than other cells due to its RGD sequence.